Clinical development with adeno-associated virus vectors

Parvoviruses

Volumn , Issue , 2005, Pages 499-510

  Carter, Barrie J ^a  

^a Targeted Genetics Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85145154961     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (41)

1. Afione, S. A., Conrad, C. K., Kearns, W. G., et al. 1996. In vivo model of adeno-associated virus vector persistence and rescue. Journal of Virology 70: 3235-41.
2. Aitken, M. L., Moss, R. B., Waltz, D. A., et al. 2001. A Phase I study of aerosolized administration of tgAAV-CF to CF subjects with mild lung disease. Human Gene Therapy 12: 1907-16.
3. Arruda, V. R., Fields, P. A., Milner, R., et al. 2001. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. Molecular Therapy 4: 586-96.
4. Beck, S. E., Jones, L. A., Chesnut, K., et al. 1999. Repeated delivery of adeno-associated virus vectors to the rabbit airway. Journal of Virology 73: 9446-55.
5. Blacklow, N. R. 1988. Adeno-associated viruses of humans. In: J. R. Pattison (ed.), Parvoviruses and Human Disease. Boca Raton: CRC Press, pp. 165-74.
6. Carter, B. J., Burstein, H. B. and Peluso, R. W. 2004. AAV vectors for gene therapy. In: N. Templeton-Smith (ed.), Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, 2nd edn. New York: Marcel Dekker, pp. 52-101.
7. Chan, J. M. K., Jin, W. W. and Stepan, T., et al. 2002. Suppression of SCW-induced arthritis with recombinant TNFR:Fc gene transfer. Molecular Therapy 6: 1-10.
8. Conrad, C. K., Allen, S. S., Afione, S. A., et al. 1996. Safety of singledose administration of an adeno-associated virus (AAV-CFTR) vector in the primate lung. Gene Therapy 3: 658-68.
9. During, M. J., Kaplitt, M. G., Stern, M. B., et al. 2001. Subthalmic GAD gene transfer in Parkinson's disease patients who are candidates for deep brain stimulation. Human Gene Therapy 12: 1589-91.
10. Emery, A. E. 2002. The muscular dystrophies. Lancet 359: 687-95.
11. Feldmann, M. and Maini, R. N. 2003. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nature Medicine 9: 1245-50.
12. Firestein, G. S. 2003. Evolving concepts of rheumatoid arthritis. Nature 423: 356-361.
13. Fischer, A. C., Beck, S. E., Smith, C. I., et al. 2003. Successful transgene expression with serial doses of aerosolized rAAV2 vectors in rhesus macaques. Molecular Therapy 8: 918-26.
14. Flotte, T. R., Zeitlin, P. L., Solow, R., et al. 1993. Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. Journal of Biological Chemistry 268: 3781-90.
15. Flotte, T. R., Afione, S. A., Solow, R., et al. 1993. In vivo delivery of adeno-associated vectors expressing the cystic fibrosis transmembrane conductance regulator to the airway epithelium. Proceedings of National Academy Science USA 93: 10163-67.
16. Flotte, T. R., Zeitlin, P. L., Reynolds, T. C., et al. 2003. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype (rAAV2)-CFTR vector in adult cystic fibrosis patients: A two-part clinical study. Human Gene Therapy 14: 1079-88.
17. Flotte, T. R., Brantly, M. L., Spencer, L. T., et al. 2004. Phase I trial of intramuscular injection of recombinant adeno-associated virus alpha-1-anti-trypsin (rAAV2-CD-hAAT) gene vector to AATdeficient adults. Human Gene Therapy 14: 93-128.
18. Greelish, J. P., Su, L. T., Lankford, E. B., et al. 1999. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nature Medicine 5: 439-43.
19. Hernandez, Y. J., Wang, J., Kearns, W. G., et al. 1999. Latent adenoassociated virus infection elicits humoral but not cell-mediated immune responses in a non-human primate model. Journal of Virology 73: 8549-58.
20. Herzog, R. W., Hagstrom, J. N., Kung, S.-H., et al. 1997. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proceedings of National Academy Science USA 94: 5804-9.
21. Chan, J. M. K., Jin, W. W. and Stepan, T., et al. 2002. Suppression of SCW-induced arthritis with recombinant TNFR:Fc gene transfer. Molecular Therapy 6: 1-10.
22. Conrad, C. K., Allen, S. S., Afione, S. A., et al. 1996. Safety of singledose administration of an adeno-associated virus (AAV-CFTR) vector in the primate lung. Gene Therapy 3: 658-68.
23. During, M. J., Kaplitt, M. G., Stern, M. B., et al. 2001. Subthalmic GAD gene transfer in Parkinson's disease patients who are candidates for deep brain stimulation. Human Gene Therapy 12: 1589-91.
24. Emery, A. E. 2002. The muscular dystrophies. Lancet 359: 687-95.
25. Feldmann, M. and Maini, R. N. 2003. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nature Medicine 9: 1245-50.
26. Firestein, G. S. 2003. Evolving concepts of rheumatoid arthritis. Nature 423: 356-361.
27. Fischer, A. C., Beck, S. E., Smith, C. I., et al. 2003. Successful transgene expression with serial doses of aerosolized rAAV2 vectors in rhesus macaques. Molecular Therapy 8: 918-26.
28. Flotte, T. R., Zeitlin, P. L., Solow, R., et al. 1993a. Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. Journal of Biological Chemistry 268: 3781-90.
29. Flotte, T. R., Afione, S. A., Solow, R., et al. 1993b. In vivo delivery of adeno-associated vectors expressing the cystic fibrosis transmembrane conductance regulator to the airway epithelium. Proceedings of National Academy Science USA 93: 10163-67.
30. Flotte, T. R., Zeitlin, P. L., Reynolds, T. C., et al. 2003. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype (rAAV2)-CFTR vector in adult cystic fibrosis patients: A two-part clinical study. Human Gene Therapy 14: 1079-88.
31. Flotte, T. R., Brantly, M. L., Spencer, L. T., et al. 2004. Phase I trial of intramuscular injection of recombinant adeno-associated virus alpha-1-anti-trypsin (rAAV2-CD-hAAT) gene vector to AATdeficient adults. Human Gene Therapy 14: 93-128.
32. Greelish, J. P., Su, L. T., Lankford, E. B., et al. 1999. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nature Medicine 5: 439-43.
33. Hernandez, Y. J., Wang, J., Kearns, W. G., et al. 1999. Latent adenoassociated virus infection elicits humoral but not cell-mediated immune responses in a non-human primate model. Journal of Virology 73: 8549-58.
34. Herzog, R. W., Hagstrom, J. N., Kung, S.-H., et al. 1997. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proceedings of National Academy Science USA 94: 5804-9.
35. Wagner, J. A., Messner, A. H., Moran, M. L., et al. 1999. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope 109: 266-74.
36. Wagner, J. A., Nepomuceno, I. B., Shah, N., et al. 1999. Maxillary sinusitis as a surrogate model for CF gene therapy clinical trials in patients with antrostomies. Journal of Gene Medicine 1: 13-21.
37. Wagner, J. A., Nepomuceno, I. B., Messner, A. H., et al. 2002. A phase ii, double-blind, randomized, placebo-controlled clinical trial of tgAAV-CF using maxillary sinus delivery in CF patients with antrostomies. Human Gene Therapy 13: 1349-59.
38. Wendtner, C. M., Nolte, A., Mangold, E., et al. 1997. Gene transfer of the costimulatory molecules B7-1 and B7-2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response. Gene Therapy 4: 726-35.
39. Xin, K. Q., Urabe, M., Yang, J., et al. 2001. A novel recombinant adenoassociated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. Human Gene Therapy 12: 1047-61.
40. Zhang, H. G., Xie, J., Yang, P., et al. 2000. Adeno-associated virus production of tumor necrosis factor receptor neutralizes tumor necrosis factor alpha and reduces arthritis. Human Gene Therapy 11: 2431-42.
41. Zhang, Y., Chirmule, N., Gao, G., Wilson, J. M. 2000. CD40 liganddependent activation of cytotoxic T lymphocytes by adenoassociated virus vectors in vivo: role of immature dendritic cells. Journal of Virology 74: 8003-10.